Ipilimumab + nivolumab in combination vs. nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort
- PMID: 40036378
- DOI: 10.1093/bjd/ljaf080
Ipilimumab + nivolumab in combination vs. nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort
Conflict of interest statement
Conflicts of interest: C.N. consults for Bristol Myers Squibb, REGENERON, Pierre Fabre, Novartis and MSD. The other authors declare no conflicts of interest.
Comment on
-
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.Br J Dermatol. 2025 May 19;192(6):1096-1105. doi: 10.1093/bjd/ljae470. Br J Dermatol. 2025. PMID: 39605282
Publication types
LinkOut - more resources
Full Text Sources